Product Description
7MW3711 is a novel antibody-drug conjugate targeting B7-H3, which is a member of the B7 ligand family and is overexpressed in most cancer types but expressed at a low level in normal tissues. The new generation antibody-drug conjugate molecule 7MW3711 with fully autonomous intellectual property right, developed based on Mabwell's novel Antibody Drug Conjugate platform IDDC™, is composed of innovative antibody molecule, novel linker, and novel payload (topoisomerase I inhibitor). When 7MW3711 enters into human body, it can specifically bind to antigens on the tumor cell membrane surface, be internalized and trafficked to the lysosome, release cytotoxic drug and induce the apoptosis of tumor cells. (Sourced from: https://www.mabwell.com/en/news_info/id-101.html)
Mechanisms of Action: B7-H3 Antagonist
Novel Mechanism: Yes
Modality: Antibody Drug Conjugate
Route of Administration: Injection
FDA Designation: Orphan Drug - Oncology Solid Tumor Unspecified *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Mabwell (Shanghai) Bioscience
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 7MW3711-2023-CP101 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-08-30 |
66% |
| 7MW3711-2023-CP102 | P2 |
Recruiting |
Oncology Solid Tumor Unspecified |
2025-08-30 |
38% |